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Autoimmune diabetes is a heterogeneous disease which can arise at any age. Subjects with adult-onset autoimmune diabetes who do 
not necessitate insulin-therapy for at least 6 months after diagnosis are demarcated as having latent autoimmune diabetes in adults 
(LADA). This condition is more heterogeneous than young-onset autoimmune diabetes and shares clinical and metabolic character-
istics with both type 2 and type 1 diabetes. Patients with LADA are considered by having highly variable β-cell destruction, different 
degrees of insulin resistance and heterogeneous titre and pattern of islet autoantibody, suggesting different pathophysiological path-
ways partially explaining the heterogeneous phenotypes of LADA. To date the heterogeneity of LADA does not allow to establish a 
priori treatment algorithm and no specific guidelines for LADA therapy are available. These subjects are mostly treated as affected 
by type 2 diabetes, a factor that might lead to the progression to insulin-dependency quickly. A personalised medicine approach is 
necessary to attain optimal metabolic control and preserve β-cell function to decrease the risk of long-term diabetes complications. 
Recent data concerning the use of oral antidiabetic agents as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor 
agonists indicate up-and-coming results in term of protect C-peptide levels and improving glycaemic control. This review summaris-
es current knowledge on LADA, emphasising controversies regarding its pathophysiology and clinical features. Moreover, we dis-
cuss data available about novel therapeutic approaches that can be considered for prevention of β-cell loss in LADA.
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lin resistance; Latent autoimmune diabetes in adults 
INTRODUCTION
Type 1 diabetes mellitus (T1DM) is an autoimmune disease de-
rived from the selective destruction of insulin-secreting β-cells 
leading to requirement of insulin therapy [1]. This condition oc-
curs in most cases during childhood or adolescence; however, 
some patients experience onset in adulthood [2]. A proportion 
of subjects with adult-onset autoimmune diabetes does not re-
quire insulin-therapy at the time of diagnosis and are clinically 
similar to patients with type 2 diabetes mellitus (T2DM). These 
patients, who were initially thought to be affected by T2DM, are 
defined as having latent autoimmune diabetes in adults (LADA) 
[3-5], a form of autoimmune diabetes, distinct from T1DM that 
shows an older age of onset and slower progression towards in-
sulin requirement [6-8].
To diagnose LADA, the Immunology of Diabetes Society has 
established three main criteria including: (1) adult age of onset 
(>30 years); (2) presence of any islet cell autoantibody; and (3) 
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absence of insulin requirement for at least 6 months after diag-
nosis [9]. However, the definition of LADA remains controver-
sial and an open debate regarding these diagnostic criteria still 
exists. Thus, patients defined as having LADA are characterized 
by genetic, phenotypic, and immunological heterogeneity, high-
ly variability of the β-cell destruction’s rate and different de-
grees of insulin resistance and autoimmunity, likely due to dif-
ferences in genetic and immune factors [10-12]. Moreover, the 
great heterogeneity of LADA makes it difficult to determine an 
a priori algorithm for treatment. A personalised therapy for 
LADA should be implemented [13]. 
This review summarizes and discusses current knowledge 
about LADA, emphasizing the differences from both T1DM 
and T2DM. In addition, we examine the results of recent studies 
about novel therapeutic approaches that could prevent β-cell 
loss in LADA.
EPIDEMIOLOGY
Most epidemiological studies suggest that adult-onset autoim-
mune diabetes is not rare as previously reported (Table 1) [5,13-
17]. Indeed, data collected from Italian registries show that the 
incidence of T1DM in subjects aged 30 to 49 years is similar to 
that of adolescents aged 15 to 19 years [18]. According to these 
data, studies among Caucasians from Northern Europe reported 
that approximately 40% of T1DM cases occur in people older 
than 30 years of age [2] and that the real incidence of this condi-
tion in subjects aged 15 to 34 years is up to three times higher 
than previously reported [19]. Data reported in LADA show 
that this is the most frequent form of adult-onset autoimmune 
diabetes and may account for 2% to 12% of all cases of diabetes 
in adult population [20]. Moreover, multicentre studies carried 
out in Europe, Asia, and North America, reported that 4% to 
14% of patients diagnosed with T2DM are positive for T1DM 
associated autoantibodies which are diagnostic for LADA 
[4,5,21-29]. However, the prevalence of LADA seems to vary 
between different countries and populations, probably due to 
differences in study design and inclusion criteria, as well as dif-
ferent life-style and ethnicity. In Action LADA, a European 
multicentre study that evaluated over 6,000 adult-onset diabetes 
patients, the overall frequency of islet cell autoantibody positiv-
ity was reported in 9.7% of subjects with T2DM, even though 
consistent differences between patients living in North and 
South Europe were found, ranging between 4% and 10%. In ac-
cordance with these data, the NonInsulin Requiring Autoim-
mune Diabetes (NIRAD study) found a cumulative frequency 
of positivity for autoantibodies (glutamic acid decarboxylase 
[GAD] and/or protein tyrosine phosphatase [IA-2]) in 5% of 
Table 1. Epidemiology of LADA [13]
Study Country Type of study No. of sample size
Age range, 
yr Autoantibody
Frequency of 
autoantibody 
positivity, %
UKPDS 25 United Kingdom Clinical based 3,672 25–65 GAD and/or ICA 12
BOTNIA Finland Registry based 1,122 28–83 GAD and/or IA-2 9.3
Ehime study Japan Clinical based 4,980 >20 GAD 3.8
ADOPT USA, Europe Clinical based 4,357 30–75 GAD and/or IA-2 4.2
NIRAD Italy Clinical based 5,330 30–75 GAD and/or IA-2 4.5
HUNT Norway Population based 1,134 ≥20 GAD 10
Tianjin China Population based 8,109 ≥15 GAD 9.2
Maioli et al. (2010) [14] Italy (Sardinia) Clinical based 5,568 35–70 GAD 4.9
Action LADA Europe Clinical based 6,810 30–70 GAD and/or IA-2, ZnT8 9.7
LADA China China Clinical based 5,324 ≥20 GAD 5.9
Maddaloni et al. (2015) [5] United Arab Emirates Clinical based 17,072 30–70 GAD and/or IA-2 2.6
Lee et al. (2009) [16] Korea Clinical based 1,370 47–62 GAD and/or IA-2 5.1
Park et al. (2011) [17] Korea Population based 884 44–60 GAD and/or IA-2, ZnT8 4.4
Roh et al. (2013) [15] Korea Clinical based 323 29–63 GAD 5.3
Adapted from Buzzetti et al., with permission from Springer Nature [13].
LADA, latent autoimmune diabetes in adults; UKPDS, United Kingdom Prospective Diabetes Study; GAD, glutamic acid decarboxylase; ICA, islet cell; 
IA-2, protein tyrosine phosphatase; NIRAD, NonInsulin Requiring Autoimmune Diabetes; ZnT8, islet-specific zinc transporter isoform 8.
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Italian patients with T2DM [25]. Similar results emerge from 
studies carried out in Asia. In the multicentre China study a fre-
quency of 5.9% was reported [30], whereas data in the Korean 
population show a prevalence ranging between 4.4% and 5.3% 
[15]. Regarding African-American, Hispanic, and Arab popula-
tions, recent studies have highlighted a lower prevalence of 
adult-onset autoimmune diabetes among these populations 
[5,31]. 
PATHOGENESIS
The spectrum of adult-onset diabetes involves all three forms of 
diabetes (T1DM, T2DM, and LADA) without defined parame-
ters. The distribution of pathological factors, such as autoimmu-
nity, insulin sensitivity and β-cell function, along a continuous 
line distinguishes categories of diabetes mellitus (Fig. 1) [13, 
28,32]. When compared with classical T1DM, LADA appears 
like the other extreme of the autoimmune diabetes spectrum, 
whereby genetic susceptibility, autoimmune response and non-
insulin-necessity presentation constitute a mild form of autoim-
mune diabetes with pathological features closer to those of 
T2DM than to those of adult T1DM, which is more similar to 
classical T1DM [13].
Genetic features 
Data available on genetic susceptibility suggest that LADA 
shows a lower genetic component [10,11,33] than T1DM. In 
particular, the human leukocyte antigen (HLA)-DRB1*04-
DQB1*0302 and HLA-DRB1*0301-DQB1*0201, which are 
very common in young-onset T1DM and decrease in frequency 
with the increasing age at disease onset, are less frequent in 
LADA than in adult-onset T1DM [25,34]. Similar findings have 
been observed for the Cyst1858Thr single-nucleotide polymor-
phism in the protein tyrosine phosphatase nonreceptor 22 
(PTPN22) gene and the insulin variable number tandem repeat 
(INS VNTR) I/I genotype expression [34,35]. Otherwise, the 
frequency of the cytotoxic T-lymphocyte–associated antigen 4 
(CTLA4) Ala49Gly polymorphism in exon 1 has been shown 
not to be associated with the age of onset of T1DM, suggesting 
a similar role in LADA susceptibility [36].
Another study carried out in Swedish and Finnish popula-
tions, showed that the frequency of T2DM associated CT/TT 
genotypes rs7903146 in the transcription factor 7 like 2 (TC-
F7L2) gene was increased in LADA subjects as in T2DM sub-
jects [37], as well as genetic similarities with T1DM have been 
observed related to HLA, INS VNTR, and PTPN22 [38]. These 
results suggest that patients with LADA may share genetic fea-
tures with both T1DM and T2DM which further supports the 
concept that LADA is an admixture of the two major types of 
diabetes [38].
However, it should be noted that most of these studies have 
investigated genes previously associated with young-onset 
T1DM or T2DM [10,39-42]. Further studies are needed to bet-
ter characterize the genetic susceptibility of LADA in order to 
establish preventive strategies as well as allow safe and effec-
tive therapies [43].
Autoimmunity 
In T1DM activated T-cells to islet-cell proteins characterize the 
lymphomononuclear cell infiltration in the endocrine pancreas 
(insulitis), causing the progressive loss of insulin-secreting 
β-cells. On the other hand, islet cell autoantibodies seem to be 
an epiphenomenon rather than pathogenic factors in β-cells de-
struction, though their detection in plasma helps to diagnose au-
toimmune diabetes. 
As a form of autoimmune diabetes, LADA is characterized by 
islet-cell specific autoantibody positivity and similar cell-medi-
ated immune response although impairment of β-cells is slower 
than in classical T1DM [6-8]. Specifically, a recent study ob-
served presence of insulitis by pancreatic scintigraphy using in-
terleukin 2 (IL-2) radiolabelled with technetium-99m (99mTc) 
and contrast-enhanced magnetic resonance imaging, providing 
evidence for the presence of activated mononuclear cells in the 
pancreas of LADA subjects, particularly within 1 year of initia-
Fig. 1. Pathogenetic features and their relation to define diabetes. 
T1DM, type 1 diabetes mellitus; LADA, latent autoimmune diabe-
tes in adults; T2DM, type 2 diabetes mellitus [32].
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tion of insulin therapy, similar to T1DM at diagnosis [44]. 
Moreover, increased pancreatic 99mTC-IL-2 uptake has been 
found in a subgroup of autoantibody-negative diabetic subjects, 
suggesting that insulitis may occur even in absence of islet-cell 
autoantibodies [45]. 
C-peptide, a marker of residual β-cell function, declines slow-
er in LADA than in T1DM. Thus, a positive correlation between 
age at diagnosis of autoimmune diabetes and fasting C-peptide 
levels has been reported [46]. Indeed, LADA subjects show 
higher stimulated C-peptide values al all time-points following 
a mixed-meal tolerance than subjects with classical T1DM [12]. 
Islet-cell autoantibodies detectable in subjects with LADA are 
the same used to identify T1DM. Glutamic acid decarboxylase 
autoantibody (GADAs) is the most sensitive marker in both 
adult-onset T1DM and LADA, whereas insulin autoantibodies, 
protein tyrosine phosphatase IA-2 (IA-2A) and islet-specific 
zinc transporter isoform 8 (ZnT8) autoantibodies, which are de-
tectable in younger T1DM patients, are positive only in a small 
percentage of LADA patients [47]. In the Action LADA study, 
68.6% of subjects screened for diabetes-associated autoantibod-
ies were positive for GADA only, 5% positive for IA-2A only 
and 2.3% positive for ZnT8A only, whereas at least two autoan-
tibody types were found in 24.1% patients [4].
To sum up and as previously mentioned, LADA shows half-
way pathological features between T1DM and T2DM. In a re-
cent Italian work, it has been suggested that different patho-
physiological could explain the heterogeneous phenotypes of 
LADA [13]. Based on this model, in patients with moderate ge-
netic susceptibility to T1DM, specific immunological factors 
can trigger an autoimmune process against islet cell antigens 
marked by the appearance of GADAs leading to β-cell apopto-
sis and insulin deficiency. On the other hand, in obese subjects 
with genetic susceptibility to T2DM, the low-grade inflamma-
tion, typical of visceral adiposity, might trigger a low-grade au-
toimmune process marked by IA-2 autoantibodies positivity, 
causing loss of β-cell function and an impairment of insulin se-
cretion (Fig. 2).
Clinical features and relation with islet autoantibody 
profile 
LADA shares clinical and metabolic features with T2DM and 
T1DM as part of a continuum of variable severity of immune 
and metabolic dysfunction [48], described as “end of the rain-
bow” (Tables 2, 3) [8]. 
Metabolic syndrome and its components (blood pressure, lip-
id profile, waist-hip ration) are less prevalent in LADA patients 
than in those with T2DM, both in Caucasians and non-Cauca-
sians subjects [5,16]. Nevertheless, this assumption changes 
when LADA patients are compared with patients with T1DM. 
The BOTNIA study [22] demonstrated that components of met-
abolic syndrome have a higher prevalence in LADA than in 
classical T1DM. Similar results emerge from the Action LADA 
project [49]. Another study, carried out in Spain, showed that 
adiposity parameters, blood pressure and triglyceride levels are 
more elevated in LADA than in T1DM but lower than in T2DM 
[50]. Similarly, data collected among a cohort of subjects with 
LADA in the United Arab Emirates showed higher body mass 
index (BMI), waist circumference, systolic blood pressure and 
glycated hemoglobin (HbA1c) values [5]. On the other hand, 
Swedish and Norwegian registers report that overweight and 
obesity are associated with increased risk of LADA [37], partic-
ularly in combination with family history for diabetes. Howev-
er, as previously discussed, LADA is characterized by a great 
phenotypic heterogeneity, witnessed by variable degrees of in-
Fig. 2. Potential pathological pathways of latent autoimmune diabetes in adults (LADA). Modified from Buzzetti et al., with permission 
from Springer Nature [13]. TCF7L2, transcription factor 7 like 2; HLA, human leukocyte antigen; INS VNTR, insulin variable number tan-
dem repeat; PTPN22, protein tyrosine phosphatase nonreceptor 22; GADA, glutamic acid decarboxylase autoantibody; IA-2A, protein tyro-
sine phosphatase IA-2. 
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sulin resistance and insulin insufficiency.
Recent evidence shows that the titre of antibody positivity, 
especially GADA, can influence clinical characteristics of sub-
jects with LADA [14,25,28]. The NIRAD study [25] demon-
strated the presence of a “bimodal distribution” of GADA titre 
in LADA sub-classifying two distinct forms of the disease. Pa-
tients with high GADA levels, typed as LADA 1, show more 
similar phenotypic features with T1DM (lower C-peptide levels, 
lower BMI, more ketosis prone) than with T2DM, whereas pa-
tients with low GADA titre, typed as LADA 2, are less ketosis 
Table 2. Differences in Clinical and Genetic Features between LADA and T2DM
LADA T2DM
Age at diagnosis >30 Years Adulthood (rarely before)
Family history of diabetes Negative or positive Frequently positive
HLA susceptibility Increased Mild increased
Onset Subclinical (rarely acute) Silent/subclinical
Rate of long-term complications at diagnosis Low High
Risk of acute complications at diagnosis Low Mild increased
C-peptide levels at diagnosis Decreased but still detectable Normal to increased
Autoimmunity Mild increased Absent
Ketosis Rare Rare
Insulin resistance Increased/no change Increased
β-Cell function Decreased Increased or normal 
Insulin requirement >6 Months after diagnosis Absent or years after diagnosis
Body mass index Normal (rarely overweight or obese) Overweight or obese
Cardiovascular risk Increased Increased
Lipid profile Normal to hypertriglyceridemia Frequently hypertriglyceridemia and/or hypercholesterolemia 
LADA, latent autoimmune diabetes in adults; T2DM, type 2 diabetes mellitus; HLA, human leukocyte antigen. 
Table 3. Differences in Clinical and Genetic Features between LADA and T1DM 
LADA T1DM
Age at diagnosis >30 Years Childhood/adolescence (rarely in adulthood)
Family history of diabetes Negative or positive Negative or positive
HLA susceptibility Increased Importantly increased
Onset Subclinical (rarely acute) Acute
Rate of long-term complications at diagnosis Low Low
Risk of acute complications at diagnosis Low Increased
C-peptide levels at diagnosis Decreased but still detectable Non detectable (rarely decreased)
Autoimmunity Mild increased Importantly increased 
Ketosis Rare Rare
Insulin resistance Mild increased Absent (rarely increased)
β-Cell function Decreased (–) Loss of function
Insulin requirement >6 Months after diagnosis At diagnosis
Body mass index Normal (rarely overweight or obese) Normal (or underweight)
Cardiovascular risk Increased Increased
Lipid profile Normal to hypertriglyceridemia Normal (especially)
LADA, latent autoimmune diabetes in adults; T1DM, type 1 diabetes mellitus; HLA, human leukocyte antigen.
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and dyslipidemia prone as compared with LADA 1, but possess 
higher frequency of obesity, hypertension, dyslipidemia, and 
cardiovascular diseases. Similar results have been found in a 
Korean population where GADA levels showed a negative cor-
relation with age of onset, total cholesterol, triglycerides, BMI, 
fasting and stimulated C-peptide, whereas a positive correlation 
was found with HbA1c and high density lipoprotein cholesterol 
[15]. The existence of two distinct subgroups of patients affect-
ed by LADA has been substantiated by genetic studies. PTPN22 
risk genotype has been associated with a high GADA titre [51], 
whereas some but not all studies, have found an association be-
tween a lower GADA titre and the TCF7L2 risk allele for 
T2DM [52]. In addition, a higher frequency of other organ-spe-
cific autoantibodies (against thyroid peroxidase, steroid 21-hy-
droxylase, tissue, tissue transglutaminase, and parietal cell) was 
detected in patients with high GADA levels, highlighting a 
more extensive autoimmune process in this subpopulation than 
in those with a lower GADA titre [53]. Accordingly, several 
studies have testified an inverse relationship between GADA ti-
tre and C-peptide levels [54], as well as more pronounced traits 
of insulin deficiency were described in patients with higher 
GADA titre [25]. Another interesting finding concerns the rela-
tionship between clinical phenotypes of LADA and specific 
GADA binding patterns. Action LADA 12 [55] demonstrated 
an association between presence of N-terminally truncated 
GAD65 autoantibodies and the clinical phenotype of T1DM in 
patients with LADA. This may have important practical impli-
cations given the relatively large number of adult patients who 
are screened for GADA, both for diabetes classification and risk 
prediction for insulin therapy. 
Even the number of islet autoantibodies in LADA appears to 
be associated with the intensity of autoimmune response. In-
deed, the United Kingdom Prospective Diabetes Study (UKP-
DS) group and the NIRAD group, have noted that the number 
of islet cell autoantibodies was directly proportional to the in-
tensity of autoimmune response, predicting more sever insulin 
insufficiency [21,47,56].
Not only the titre, but also different patterns of antibody posi-
tivity could influence clinical features of LADA patients. In a 
cohort of approximately 17,000 subjects affected by LADA, the 
positivity for IA-2A only was associated with a clinical pheno-
type more similar to T2DM, whereas subjects positive for both 
IA-2A and GADA were more similar to T1DM [5]. Other au-
thors observed that IA-2A was the only autoantibody that 
showed increased frequency with increasing BMI in patients af-
fected by T2DM [57]. However, conflicting data have been re-
ported. In the Action LADA 7 patients positive for at least two 
autoantibodies compared with those positive for a single anti-
body did not show relevant differences in demographic or clini-
cal parameters [4]. Moreover, mixed results about the correla-
tion between GADA titre and length of insulin-free period have 
been reported [14,22,54,58]. 
NATURAL HISTORY OF LADA
To date, only few data related to the development of late diabet-
ic complications have been reported in patients with LADA.
Microvascular complications
There are only few studies related to the occurrence of micro-
vascular complications (nephropathy, retinopathy, neuropathy) 
in LADA and controversial results have been reported, partly 
due to a substantial heterogeneity regarding disease duration of 
study’s subjects. Limited to patients with a short disease dura-
tion, microvascular complications in LADA appear to be less 
frequent than in patients affected by T2DM. In particular, the 
Fremantle Diabetes Study [59], showed less frequency of mi-
croalbuminuria in patients with a recent diagnosis of LADA 
than in those with T2DM. In addition, in the same study an as-
sociation between GADA positivity and a reduced risk of devel-
oping microalbuminuria during a follow-up period (<5 years) 
was found. In a study among Chinese subjects [60], it was ob-
served that the onset of nephropathy and retinopathy is less 
common in patients with a recent diagnosis (<5 years) of 
LADA than in those affected by T2DM. However, these find-
ings could be explained by the fact that subjects with T2DM are 
usually diagnosed later than subjects with LADA, being chroni-
cally expose to hyperglycaemia which may ultimately lead to 
microvascular complications. Thus, studies evaluating patients 
with a disease duration >5 years did not find differences be-
tween LADA and T2DM with respect to the prevalence of ne-
phropathy or retinopathy, as well as no association was found 
between GADA positivity and rate of microvascular complica-
tions [61-63]. However, the BOTNIA study [64] observed that 
patients with a disease duration >5 years had an increased risk 
of retinopathy; in addition, the rate of neuropathy appears more 
prevalent in LADA than in T2DM [59,62,64,65].
Macrovascular complications
A lower risk of macrovascular complications—including coro-
nary heart disease, stroke, peripheral artery disease—could be 
postulated on the basis of the healthier metabolic profile of pa-
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tients with LADA respect to those with T2DM. However, cur-
rent data showed similar cardiovascular outcomes in LADA and 
T2DM. In the BOTNIA study [64] no statistically significant 
differences were found in respect to coronary heart disease, 
stroke, overall mortality, and cardiovascular mortality between 
LADA and T2DM. Similar results emerged from other indepen-
dent studies. The Fremantle Diabetes Study [59] did not evi-
denced different rate of cardiovascular disease and mortality in 
LADA versus T2DM, while the HUNT2 study observed similar 
increase of cardiovascular risk in patients positive for GAD an-
tibodies and in those who were negative, compared to non-dia-
betic patients [66]. Altogether, these results suggest that differ-
ent pathogenetic mechanisms might modulate the onset of mac-
rovascular complications in LADA, regardless of the metabolic 
profile.
Fracture risk
Impaired bone metabolism and increased risk of fractures have 
been observed in both T1DM and T2DM [67], partly due to re-
duction of bone formation. A recent cross-sectional study [68], 
showed that bone resorption is reduced in both LADA and 
T2DM compared to non-diabetic subjects whereas circulating 
sclerostin—which is an antagonist of the osteoblastic bone for-
mation—is increased in T2DM only, probably due to the asso-
ciation between sclerostin levels and metabolic syndrome which 
is more prevalent in T2DM than in LADA. However, these data 
suggest that pathways involved in bone metabolism differ be-
tween these two types of diabetes and further studies are needed 
to clarify the pathogenesis of bone impairment and explore the 
potential role of sclerostin on bone fragility associated with dia-
betes.
TREATMENT OF LADA
To date, no specific guidelines for treatment of subjects affected 
by LADA have been published. Therefore, these subjects are 
mostly treated as affected by T2DM resulting in rapid progres-
sion to an insulin-dependent state [13], especially in patients 
who present with clinical and biochemical features closer to 
T1DM than T2DM [5,69]. In addition, a correct therapeutic 
strategy for LADA patients should aim to the preservation of re-
sidual β-cell function as well as improvement of glucometabolic 
control, in order to reduce the risk of long-term complications. 
Maintenance of β-cell function, as demonstrated by the Diabe-
tes Control and Complication Trial, is indeed associated with a 
reduction of long teen diabetic complications [70]. 
Sulphonylurea
A small randomized controlled trial, carried out in Japan, com-
pared glibenclamide with insulin treatment in subjects affected 
by LADA. Results showed worsening metabolic control and 
progressive deterioration of β-cell function as measured by sig-
nificant reduction of stimulated C-peptide ratio after 30 months 
follow-up in patients treated with sulphonylurea [71]. Similar 
results have been reported in the Tokyo study [72], a multi-
center, randomized, nonblinded clinical study that evaluated 
4,089 noninsulin-dependent LADA patients with a 5-year or 
shorter duration of diabetes. In this study Maruyama et al. [72] 
demonstrated that the progression rate to insulin-dependency in 
the sulphonylurea group was higher than that in the insulin 
group, and C-peptide during the oral glucose tolerance test was 
more preserved in patients undergoing insulin therapy. Alto-
gether, these data suggest that sulphonylurea should not be used 
as first-line therapy in patients with LADA.
Insulin therapy
There insulin treatment is essential in all patients with complete 
β-cell loss and represents the most straightforward therapy for 
replacing missing endogenous insulin secretion [13]. However, 
subjects with a recent diagnosis of LADA are characterized by 
some degree of preservation of β-cell function as shown by 
higher C-peptide levels, and progress slower to absolute insulin 
dependency. Nevertheless, consistent data from randomized 
clinical trials highlight the importance of an early initiation of 
insulin therapy in LADA regardless of presence of some endog-
enous insulin secretion. The rationale behind this approach is to 
improve metabolic control while protecting β-cell function. 
Even though the pathophysiological basis of the protective ef-
fect of insulin therapy is not well known, several preclinical 
studies showed that therapy with exogenous insulin would sup-
port β-cell function, reducing the hyperglycaemic stress [73] 
and decreasing severity of insulitis [74]. Other studies suggest 
the promotion of T helper 2 immunity and activation of insulin-
specific regulatory T-cells mediated by the exposure to exoge-
nous insulin [75,76]. Moreover, a suppression of autoreactive T-
cells through local release of regulatory cytokines has been sug-
gested in patients treated with insulin [77].
Preservation of β-cell function: next frontiers in LADA 
therapy
An intervention intended to preserve β-cell function should be 
pursued in patients with LADA. Recent immune-intervention 
trials have achieved promising results in term of preserving 
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stimulated C-peptide levels and improving glycaemic control 
[78-80]. However, some drugs currently used for treatment of 
T2DM might be considered in LADA.
Dipeptidyl peptidase 4 (DPP-4) inhibitors represent a class of 
oral antidiabetic agents frequently used in T2DM which have 
been shown to preserve β-cell function and reduce insulitis in 
patients with T2DM as well as in mouse models of autoimmune 
diabetes [81-83], suggesting that they might be a valuable treat-
ment option in LADA. A recent randomized-controlled study 
conducted in China [84] has observed that treatment with sita-
gliptin in addition to insulin preserved C-peptide concentration 
better than insulin alone in patients with LADA over a 1-year 
period. Similarly, sitagliptin improved glycaemic control in 
adults with T1DM [85]. Furthermore, Johansen et al. [86] have 
reported that another DPP-4 inhibitor, linagliptin, attenuated de-
cline of C-peptide in LADA patients over a 2-year study period. 
In a post hoc analysis of data pooled from five randomized, pla-
cebo-controlled studies [87], saxagliptin was effective in lower-
ing blood glucose levels and well tolerated in GADA-positive 
patients. Moreover, compared with placebo saxagliptin ap-
peared to increase C-peptide levels at 24 weeks follow-up.
Other interesting findings come from our study of a post hoc 
analysis investigating treatment with dulaglutide, a glucagon-
like peptide 1 receptor agonist (GLP-1RA) [88] in patients with 
T2DM among whom there were some GAD antibody positive 
patients. The effectiveness of dulaglutide in subjects with 
LADA was indicated by reduction of HbA1c and increase of 
β-cell function, without affecting the rate of hypoglycaemia 
over 1-year observation period. This study is the first to indicate 
that dulaglutide is an effective anti-hyperglycaemic treatment in 
T2DM patients positive for GAD antibodies. Taking together 
these data highlight the potential long-term effects of DPP-4 
and GLP-1RA in patients with LADA. However, further studies 
with larger cohort and longer treatment duration are needed to 
assess whether these therapies translate into a reduced progres-
sion to insulin dependence and diabetic complications [87].
CONCLUSIONS
Adult-onset autoimmune diabetes is a heterogeneous disease 
with clinical and metabolic features ranging from classical 
T1DM with onset from childhood to adult age, to LADA. When 
defined according to the criteria proposed by the Immunology 
of Diabetes Society, LADA also is characterized by significant 
degree of heterogeneity, encompassing different clinical pheno-
types, ranging from prevalent insulin resistance to prevalent in-
sulin deficiency associated with severe or mild markers of auto-
immunity [47]. However, mid-way features between T1DM and 
Fig. 3. Algorithm for diagnosis and therapy of latent autoimmune diabetes in adults (LADA). BMI, body mass index; T2DM, type 2 diabe-
tes mellitus; GADA, glutamic acid decarboxylase autoantibody; DPP-4, dipeptidyl peptidase 4.
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T2DM are recognised in patients affected by LADA. The titre 
of antibody positivity [14,25,28], especially GADA, as well as 
the recognition of different patterns of autoantibody positivity 
[5] can influence the clinical features of LADA and may be use-
ful for diabetes classification and prediction of risk for insulin 
therapy. 
Epidemiological studies show that LADA is a prevalent form 
of diabetes and may account for 2% to 12% of all cases of dia-
betes in adult population [20]. Moreover, 4% to 14% of patients 
diagnosed with T2DM are positive for T1DM associated auto-
antibodies which are diagnostic for LADA [4,5,14,21-29]. For 
this reason, when diagnosing diabetes in adult age, a diagnosis 
of LADA should be always considered, especially when clinical 
features are suggestive of this form of diabetes.
To date, an a priori algorithm for treatment of LADA does 
not exist [13]. However, a personalized medicine approach is 
requested to achieve optimal metabolic control and preserve 
β-cell function, which is associated with a lower risk of occur-
rence of long-term diabetes complications.
In this regard, several data showed that insulin treatment, as 
well as DPP-4 agents, can sustain residual β-cell function [81-
88]. Insulin therapy (basal), at low dose can be prescribed to 
LADA patients with DPP-4 as an additional weapon, whereas 
sulphonylurea may hasten insulin dependency and should not 
be used as first-line therapy for patients with LADA (Fig. 3). 
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